Projects per year
Abstract
Acute myeloid leukemia (AML) is a heterogeneous disease caused by different mutations. Previously, we showed that each mutational subtype develops its specific gene regulatory network (GRN) with transcription factors interacting within multiple gene modules, many of which are transcription factor genes themselves. Here, we hypothesize that highly connected nodes within such networks comprise crucial regulators of AML maintenance. We test this hypothesis using FLT3-ITD-mutated AML as a model and conduct an shRNA drop-out screen informed by this analysis. We show that AML-specific GRNs predict crucial regulatory modules required for AML growth. Furthermore, our work shows that all modules are highly connected and regulate each other. The careful multi-omic analysis of the role of one (RUNX1) module by shRNA and chemical inhibition shows that this transcription factor and its target genes stabilize the GRN of FLT3-ITD+ AML and that its removal leads to GRN collapse and cell death.
Original language | English |
---|---|
Article number | 113568 |
Journal | Cell Reports |
Volume | 42 |
Issue number | 12 |
Early online date | 15 Dec 2023 |
DOIs | |
Publication status | Published - 26 Dec 2023 |
Bibliographical note
AcknowledgmentsWe are grateful to the Genomics Birmingham Facility and to the University of Birmingham Flow Cytometry platform for their expert services. This work as funded by a grant from the Medical Research Council UK to C.B., O.H., and P.N.C. (MR/S021469/1), by a grant from Blood Cancer UK to C.B. and P.N.C. (15001), and by a grant from the National Institutes of Health to J.B. (R01 CA234478). D.J.L.C. is a John Goldman Fellow of Leukemia UK (2021/JGF/001).
Copyright © 2023 The Authors.
Keywords
- Humans
- Gene Regulatory Networks
- Regulon
- Leukemia, Myeloid, Acute/genetics
- Mutation/genetics
- RNA, Small Interfering
- fms-Like Tyrosine Kinase 3/genetics
Fingerprint
Dive into the research topics of 'Gene regulatory network analysis predicts cooperating transcription factor regulons required for FLT3-ITD+ AML growth'. Together they form a unique fingerprint.Projects
- 2 Finished
-
Pharmaceutical targeting of RAS in Acute Myeloid Leukaemia with RAS mutations or FLT3-ITD
Coleman, D. (Principal Investigator)
1/01/22 → 29/02/24
Project: Research
-
Finding therapeutic targets in FLT3-ITD AML using a systems biology approach
Cockerill, P. (Co-Investigator) & Bonifer, C. (Principal Investigator)
1/09/19 → 31/12/23
Project: Research Councils